Freestone Grove Partners’s Centessa Pharmaceuticals CNTA Stock Holding History

Freestone Grove Partners’s Portfolio CNTA Stock Details CNTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-109,327	Closed	-$4.34M	–	1076
2026 Q1	$4.34M	Buy	+109,327	New	+$2.8M	0.03%	332

Freestone Grove Partners's CNTA Position: Q2 2026 in Review

Freestone Grove Partners sold out of Centessa Pharmaceuticals (CNTA) in Q2 2026, closing a stake of 109,327 shares — an estimated $4.34M sold.

Freestone Grove Partners first reported a position in CNTA in Q1 2026 and held it in 1 quarter. The position peaked at $4.34M in Q1 2026. 0 funds tracked by Wall St. Rank hold CNTA as of Q2 2026.

Freestone Grove Partners reported no remaining Centessa Pharmaceuticals position as of Q2 2026 after selling out during the quarter.
Freestone Grove Partners sold 109,327 Centessa Pharmaceuticals shares in Q2 2026, an estimated $4.34M.
Freestone Grove Partners first reported a position in Centessa Pharmaceuticals in Q1 2026 and held it in 1 quarter.
Freestone Grove Partners's Centessa Pharmaceuticals position peaked at $4.34M in Q1 2026.
0 funds tracked by Wall St. Rank held Centessa Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.